The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor
Quintana, F. J., Basso, A. S., Iglesias, A. H., Korn, T., Farez, M. F., Bettelli, E., Caccamo, M., Oukka, M., & Weiner, H. L. (2008) · Nature · doi:10.1038/nature06880 · Cited by 1,865
Regulatory T cells in cancer immunotherapy
Tanaka, A., & Sakaguchi, S. (2017) · Cell Research · doi:10.1038/cr.2016.151 · Cited by 1,860
Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T., & Gajewski, T. F. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006504 · Cited by 1,677
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins
Veldhoen, M., Hirota, K., Westendorf, A. M., Buer, J., Dumoutier, L., Renauld, J.-C., & Stockinger, B. (2008) · Nature · doi:10.1038/nature06881 · Cited by 1,634
An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells
Mezrich, J. D., Fechner, J. H., Zhang, X., Johnson, B. P., Burlingham, W. J., & Bradfield, C. A. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903670 · Cited by 1,601
Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health
Cervenka, I., Agudelo, L. Z., & Ruas, J. L. (2017) · Science · doi:10.1126/science.aaf9794 · Cited by 1,382
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Munn, D. H., Sharma, M. D., Baban, B., Harding, H. P., Zhang, Y., Ron, D., & Mellor, A. L. (2005) · Immunity · doi:10.1016/j.immuni.2005.03.013 · Cited by 1,272
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
Aryl Hydrocarbon Receptor Antagonists Promote the Expansion of Human Hematopoietic Stem Cells
Boitano, A. E., Wang, J., Romeo, R., Bouchez, L. C., Parker, A. E., Sutton, S. E., Walker, J. R., Flaveny, C. A., Perdew, G. H., Denison, M. S., et al. (2010) · Science · doi:10.1126/science.1191536 · Cited by 1,047
T cell apoptosis by tryptophan catabolism
Fallarino, F., Grohmann, U., Vacca, C., Bianchi, R., Orabona, C., Spreca, A., Fioretti, M. C., & Puccetti, P. (2002) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401073 · Cited by 1,022
Antitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
Tumor-associated macrophages: from basic research to clinical application
Yang, L., & Zhang, Y. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0430-2 · Cited by 847
Apetoh, L., Quintana, F. J., Pot, C., Joller, N., Xiao, S., Kumar, D., Burns, E. J., Sherr, D. H., Weiner, H. L., & Kuchroo, V. K. (2010) · Nature Immunology · doi:10.1038/ni.1912 · Cited by 725
The Search for Endogenous Activators of the Aryl Hydrocarbon Receptor
Nguyen, L. P., & Bradfield, C. A. (2008) · Chemical Research in Toxicology · doi:10.1021/tx7001965 · Cited by 709
Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells
Pallotta, M. T., Orabona, C., Volpi, C., Vacca, C., Belladonna, M. L., Bianchi, R., Servillo, G., Brunacci, C., Calvitti, M., Bicciato, S., et al. (2011) · Nature Immunology · doi:10.1038/ni.2077 · Cited by 703
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Platten, M., Wick, W., & Van den Eynde, B. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0569 · Cited by 703
Nguyen, N. T., Kimura, A., Nakahama, T., Chinen, I., Masuda, K., Nohara, K., Fujii-Kuriyama, Y., & Kishimoto, T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014465107 · Cited by 685
DiNatale, B. C., Murray, I. A., Schroeder, J. C., Flaveny, C. A., Lahoti, T. S., Laurenzana, E. M., Omiecinski, C. J., & Perdew, G. H. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq024 · Cited by 634
Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 634
Curtsinger, J. M., Valenzuela, J. O., Agarwal, P., Lins, D., & Mescher, M. F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4465 · Cited by 630
Wainwright, D. A., Chang, A. L., Dey, M., Balyasnikova, I. V., Kim, C. K., Tobias, A., Cheng, Y., Kim, J. W., Qiao, J., Zhang, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0514 · Cited by 576
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Pilotte, L., Larrieu, P., Stroobant, V., Colau, D., Dolušić, E., Frédérick, R., De Plaen, E., Uyttenhove, C., Wouters, J., Masereel, B., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113873109 · Cited by 572
Spranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-3 · Cited by 552
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity
Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M. J., Thomas, B., Rupar, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-246124 · Cited by 548
Wainwright, D. A., Balyasnikova, I. V., Chang, A. L., Ahmed, A. U., Moon, K.-S., Auffinger, B., Tobias, A. L., Han, Y., & Lesniak, M. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2130 · Cited by 472
Sugimoto, H., Oda, S.-I., Otsuki, T., Hino, T., Yoshida, T., & Shiro, Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508996103 · Cited by 441
Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division
Lee, G. K., Park, H. J., Macleod, M., Chandler, P., Munn, D. H., & Mellor, A. L. (2002) · Immunology · doi:10.1046/j.1365-2567.2002.01526.x · Cited by 432
Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses
Kimura, A., Naka, T., Nakahama, T., Chinen, I., Masuda, K., Nohara, K., Fujii-Kuriyama, Y., & Kishimoto, T. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090560 · Cited by 412
Aryl hydrocarbon receptor Controls Monocyte Differentiation into dendritic Cells versus Macrophages
Goudot, C., Coillard, A., Villani, A.-C., Gueguen, P., Cros, A., Sarkizova, S., Tang-Huau, T.-L., Bohec, M., Baulande, S., Hacohen, N., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.016 · Cited by 382
AhR sensing of bacterial pigments regulates antibacterial defence
Moura-Alves, P., Faé, K., Houthuys, E., Dorhoi, A., Kreuchwig, A., Furkert, J., Barison, N., Diehl, A., Munder, A., Constant, P., et al. (2014) · Nature · doi:10.1038/nature13684 · Cited by 369
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Moon, Y. W., Hajjar, J., Hwu, P., & Naing, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0094-9 · Cited by 336
Wagner, J. E., Brunstein, C. G., Boitano, A. E., DeFor, T. E., McKenna, D., Sumstad, D., Blazar, B. R., Tolar, J., Le, C., Jones, J., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2015.10.004 · Cited by 335
Litzenburger, U. M., Opitz, C. A., Sahm, F., Rauschenbach, K. J., Trump, S., Winter, M., Ott, M., Ochs, K., Lutz, C., Liu, X., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1637 · Cited by 322
Activation of the Ah Receptor Signal Transduction Pathway by Bilirubin and Biliverdin
Phelan, D., Winter, G. M., Rogers, W. J., Lam, J. C., & Denison, M. S. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0814 · Cited by 318
Beatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Bowman, K. J., Scherle, P. A., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2272 · Cited by 314
Yeste, A., Nadeau, M., Burns, E. J., Weiner, H. L., & Quintana, F. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120611109 · Cited by 302
Keeping the eIF2 alpha kinase Gcn2 in check
Castilho, B. A., Shanmugam, R., Silva, R. C., Ramesh, R., Himme, B. M., & Sattlegger, E. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.04.006 · Cited by 297
Yue, E. W., Sparks, R., Polam, P., Modi, D., Douty, B., Wayland, B., Glass, B., Takvorian, A., Glenn, J., Zhu, W., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00391 · Cited by 295
Spranger, S. (2016) · International Immunology · doi:10.1093/intimm/dxw014 · Cited by 290
Kim, S.-H., Henry, E. C., Kim, D.-K., Kim, Y.-H., Shin, K. J., Han, M. S., Lee, T. G., Kang, J.-K., Gasiewicz, T. A., Ryu, S. H., et al. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.021832 · Cited by 286
Wincent, E., Amini, N., Luecke, S., Glatt, H., Bergman, J., Crescenzi, C., Rannug, A., & Rannug, U. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808321200 · Cited by 279
A ligand for the aryl hydrocarbon receptor isolated from lung
Song, J., Clagett-Dame, M., Peterson, R. E., Hahn, M. E., Westler, W. M., Sicinski, R. R., & DeLuca, H. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232562899 · Cited by 264
Yamada, T., Horimoto, H., Kameyama, T., Hayakawa, S., Yamato, H., Dazai, M., Takada, A., Kida, H., Bott, D., Zhou, A. C., et al. (2016) · Nature Immunology · doi:10.1038/ni.3422 · Cited by 251
Koblish, H. K., Hansbury, M. J., Bowman, K. J., Yang, G., Neilan, C. L., Haley, P. J., Burn, T. C., Waeltz, P., Sparks, R. B., Yue, E. W., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0628 · Cited by 242
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors
Röhrig, U. F., Majjigapu, S. R., Vogel, P., Zoete, V., & Michielin, O. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00326 · Cited by 204
Öberg, M., Bergander, L., Håkansson, H., Rannug, U., & Rannug, A. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfi154 · Cited by 163
Hsu, Y.-L., Hung, J.-Y., Chiang, S.-Y., Jian, S.-F., Wu, C.-Y., Lin, Y.-S., Tsai, Y.-M., Chou, S.-H., Tsai, M.-J., & Kuo, P.-L. (2016) · Oncotarget · doi:10.18632/oncotarget.8488 · Cited by 158
Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor
Shin, J. H., Zhang, L. H., Murillo, O., Kim, J., Kohrt, H. E. K., Bui, J. D., & Sunwoo, J. B. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302856110 · Cited by 155
AHR Function in Lymphocytes: Emerging Concepts
Zhou, L. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.11.007 · Cited by 146
Li, M., Bolduc, A. R., Hoda, M. N., Gamble, D. N., Dolisca, S.-B., Bolduc, A., Hoang, K., Ashley, C., McCall, D. C., Rojiani, A. M., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-21 · Cited by 144
Opitz, C. A., Litzenburger, U. M., Opitz, U., Sahm, F., Ochs, K., Lutz, C., Wick, W., & Platten, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019823 · Cited by 143
Breast Cancer Stem-Like Cells Are Inhibited by a Non-Toxic Aryl Hydrocarbon Receptor Agonist
Prud’homme, G. J., Glinka, Y., Toulina, A., Ace, O., Subramaniam, V., & Jothy, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013831 · Cited by 143
Peng, Y., Ueng, S., Tseng, C., Hung, M., Song, J., Wu, J., Liao, F.-Y., Fan, Y.-S., Wu, M.-H., Hsiao, W., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01390 · Cited by 141
Jochéms, C., Fantini, M. C., Fernando, R. I., Kwilas, A. R., Donahue, R. N., Lepone, L. M., Grenga, I., Kim, Y., Brechbiel, M. W., Gulley, J. L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9326 · Cited by 139
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 132
Soshilov, A. A., & Denison, M. S. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01183-13 · Cited by 128
Smirnova, A. V., Wincent, E., Bergander, L. V., Alsberg, T. E., Bergman, J., Rannug, A., & Rannug, U. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00416 · Cited by 126
Hall, J. M., Barhoover, M. A., Kazmin, D. A., McDonnell, D. P., Greenlee, W. F., & Thomas, R. S. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0346 · Cited by 112
The Aryl Hydrocarbon Receptor Promotes IL-10 Production by NK Cells
Wagage, S., John, B., Krock, B. L., Hall, A. O., Randall, L. M., Karp, C. L., Simon, M. C., & Hunter, C. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1300497 · Cited by 112
Lewis-Ballester, A., Forouhar, F., Kim, S.-M., Lew, S., Wang, Y., Karkashon, S., Seetharaman, J., Batabyal, D., Chiang, B., Hussain, M., et al. (2016) · Scientific Reports · doi:10.1038/srep35169 · Cited by 107
O’Donnell, E. F., Koch, D. C., Bisson, W. H., Jang, H. S., & Kolluri, S. K. (2014) · Cell Death and Disease · doi:10.1038/cddis.2013.549 · Cited by 105
Kristeleit, R. S., Давиденко, І., Shirinkin, V., El-Khouly, F., Bondarenko, I., Goodheart, M. J., Горбунова, В. А., Penning, C. A., Shi, J. G., Liu, X., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.005 · Cited by 102
Zhang, S., Kim, K., Jin, U. H., Pfent, C. M., Cao, H., Amendt, B. A., Liu, X., Wilson-Robles, H. M., & Safe, S. H. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0548 · Cited by 100
Lessons Learned from Two Decades of Anticancer Drugs
Liu, Z., Delavan, B., Roberts, R. A., & Tong, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.005 · Cited by 95
Perez, R. P., Riese, M. J., Lewis, K. D., Saleh, M. N., DAUD, A. I., Berlin, J. D., Lee, J. J., Mukhopadhyay, S., Zhou, L., Serbest, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3003 · Cited by 95
Manlapat, A., Kahler, D. J., Chandler, P., Munn, D. H., & Mellor, A. L. (2007) · European Journal of Immunology · doi:10.1002/eji.200636690 · Cited by 92
The end of the road for the tryptophan depletion concept in pregnancy and infection
Badawy, A. A.-B., Namboodiri, A. M. A., & Moffett, J. R. (2016) · Clinical Science · doi:10.1042/cs20160153 · Cited by 92
Orabona, C., Belladonna, M. L., Vacca, C., Bianchi, R., Fallarino, F., Volpi, C., Gizzi, S., Fioretti, M. C., Grohmann, U., & Puccetti, P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.6582 · Cited by 88
Siu, L. L., Gelmon, K. A., Chu, Q. S.-C., Pachynski, R. K., Alese, O. B., Basciano, P. A., Walker, J., Mitra, P., Zhu, L., Phillips, P., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct116 · Cited by 88
Wang, C., Ye, Z., Kijlstra, A., Zhou, Y.-J., & Yang, P. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12352 · Cited by 86
Hanihara, M., Kawataki, T., Oh‐oka, K., Mitsuka, K., Nakao, A., & Kinouchi, H. (2015) · Journal of neurosurgery · doi:10.3171/2015.5.jns141901 · Cited by 85
Cancer Precision Medicine: From Cancer Screening to Drug Selection and Personalized Immunotherapy
Deng, X., & Nakamura, Y. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.013 · Cited by 83
Marconett, C. N., Sundar, S. N., Poindexter, K. M., Stueve, T. R., Bjeldanes, L. F., & Firestone, G. L. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-08-0689 · Cited by 75
Lara, P. N., Bauer, T. M., Hamid, O., Smith, D. C., Gajewski, T. F., Gangadhar, T. C., Somer, B. G., Schmidt, E. V., Zhao, Y., Gowda, H. N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4515 · Cited by 67
Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy
Miyazaki, T., Moritake, K., Yamada, K., Hara, N., Osago, H., Shibata, T., Akiyama, Y., & Tsuchiya, M. (2009) · Journal of neurosurgery · doi:10.3171/2008.10.jns081141 · Cited by 66
A Proposed Mechanism for the Protective Effect of Dioxin against Breast Cancer
Hsu, E. L., Yoon, D. S., Choi, H. H., Wang, F., Taylor, R. T., Chen, N., Zhang, R., & Hankinson, O. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm125 · Cited by 65
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor
Moyer, B. J., Rojas, I. Y., Murray, I. A., Lee, S., Hazlett, H. F., Perdew, G. H., & Tomlinson, C. R. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.03.012 · Cited by 65
Sonner, J. K., Deumelandt, K., Ott, M., Thomé, C. M., Rauschenbach, K. J., Schulz, S., Munteanu, B., Mohapatra, S., Adam, I., Hofer, A.-C., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1240858 · Cited by 64
Smith, D. C., Gajewski, T. F., Hamid, O., Wasser, J. S., Olszanski, A. J., Patel, S. P., Mamtani, R., Schmidt, E. V., Zhao, Y., Maleski, J. E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4503 · Cited by 63
Structural and functional analyses of human tryptophan 2,3-dioxygenase
Meng, B., Wu, D., Gu, J., Ouyang, S., Ding, W., & Liu, Z. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24653 · Cited by 60
Parks, A. J., Pollastri, M. P., Hahn, M. E., Stanford, E. A., Novikov, O., Franks, D. G., Haigh, S. E., Narasimhan, S., Ashton, T. D., Hopper, T. G., et al. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.093369 · Cited by 60
Eleftheriadis, T., Pissas, G., Antoniadi, G., Liakopoulos, V., & Stefanidis, I. (2015) · Immunology · doi:10.1111/imm.12502 · Cited by 58
Indoleamine 2,3-Dioxygenase (IDO)
Scheler, M., Wenzel, J., Tüting, T., Takikawa, O., Bieber, T. R. M., & von Bubnoff, D. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070281 · Cited by 57
Ochs, K., Ott, M., Rauschenbach, K. J., Deumelandt, K., Sahm, F., Opitz, C. A., von Deimling, A., Wick, W., & Platten, M. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13503 · Cited by 55
Tigges, J., Haarmann‐Stemmann, T., Vogel, C. F. A., Grindel, A., Hübenthal, U., Brenden, H., Grether‐Beck, S., Vielhaber, G., Johncock, W., Krutmann, J., et al. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.362 · Cited by 54
Targeting TDO in cancer immunotherapy
Yu, C., Song, Y., Zhu, Z., Huang, B., Xiao, Y.-Q., & Luo, D. (2017) · Medical Oncology · doi:10.1007/s12032-017-0933-2 · Cited by 52
Spira, A. I., Hamid, O., Bauer, T. M., Borges, V. F., Wasser, J. S., Smith, D. C., Clark, A. S., Schmidt, E. V., Zhao, Y., Maleski, J. E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.1103 · Cited by 43
Advances in indoleamine 2,3-dioxygenase 1 medicinal chemistry
Coletti, A., Greco, F. A., Dolciami, D., Camaioni, E., Sardella, R., Pallotta, M. T., Volpi, C., Orabona, C., Grohmann, U., & Macchiarulo, A. (2017) · MedChemComm · doi:10.1039/c7md00109f · Cited by 42
Wu, Y. K., Xu, T., Liu, J., Ding, K., & Xu, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.04.061 · Cited by 41
Komrokji, R. S., Wei, S., Mailloux, A. W., Zhang, L., Padron, E., Sallman, D. A., Lancet, J. E., Tinsley, S., Nardelli, L. A., Pinilla-Ibarz, J. A., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.12.005 · Cited by 40
High-Throughput Fluorescence-Based Screening Assays for Tryptophan-Catabolizing Enzymes
Willemsen‐Seegers, N., van Doornmalen, A. M., Uitdehaag, J. C. M., de Man, J., Buijsman, R. C., & Zaman, G. J. R. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114536616 · Cited by 39
Hamid, O., Bauer, T. M., Spira, A. I., Smith, D. C., Olszanski, A. J., Tarhini, A. A., Lara, P. N., Gajewski, T. F., Wasser, J. S., Patel, S. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.3012 · Cited by 37
Moreno, A. C. R., Clara, R. O., Coimbra, J. B., Julio, A. R., Albuquerque, R. C., de Oliveira, E. M., Maria–Engler, S. S., & Čampa, A. (2013) · FEBS Journal · doi:10.1111/febs.12444 · Cited by 35
Wang, T., Wyrick, K. L., Meadows, G. G., Wills, T. B., & Vorderstrasse, B. A. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr247 · Cited by 35
Tumang, J. R., Gomes, B., Wythes, M. J., Crosignani, S., Bingham, P., Bottemanne, P., Cannelle, H., Cauwenberghs, S., Chaplin, J., Dalvie, D., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-4863 · Cited by 27
The diverse and important contributions of the AHR to cancer and cancer immunity
Wang, Z., Monti, S., & Sherr, D. H. (2017) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2017.01.008 · Cited by 22
Binding Properties of Different Categories of Ido1 Inhibitors: A Microscale Thermophoresis Study
Greco, F. A., Coletti, A., Custodi, C., Dolciami, D., Michele, A. D., Carotti, A., Marinozzi, M., Schlinck, N., & Macchiarulo, A. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0022 · Cited by 10
Komrokji, R. S., Wei, S., Mailloux, A. W., et al. (2014) · Blood · doi:10.1182/blood.v124.21.4653.4653 · Cited by 7
Cited by
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Lieu, E. L., Nguyen, T., Rhyne, S., & Kim, J. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0375-3 · Cited by 818
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
Maynard, A., McCoach, C. E., Rotow, J. K., Harris, L., Haderk, F., Kerr, D. L., Yu, E. A., Schenk, E. L., Tan, W., Zee, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.017 · Cited by 685
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Tie, Y., Tang, F., Wei, Y.-Q., & Wei, X.-W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01282-8 · Cited by 591
Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance
Khalaf, K., Hana, D., Chou, J. T.-T., Singh, C., Mackiewicz, A., & Kaczmarek, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656364 · Cited by 513
Metadata
- Authors
- Cheong, J. E., & Sun, L.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 39
- Issue
- 3
- Pages
- 307-325
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W2775687989
- Cited by
- 487
- References
- 102
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.